Optimized aptamer-based impedimetric assay for sensitive and selective determination of moxifloxacin
Abstract
Moxifloxacin (MOX) is a broad-spectrum fluoroquinolone antibiotic used in the treatment of various bacterial infections, including acute exacerbation of chronic bronchitis, community-acquired pneumonia, skin and soft tissue infections, complicated intraabdominal infections, and conjunctivitis. Due to the growing global concern over antibiotic resistance, it is essential to monitor MOX levels in critical cases to ensure therapeutic efficacy and minimize toxicity. Personalized treatment strategies and rapid point-of-care drug monitoring are critical for preventing resistance and optimizing patient outcomes. In this study, an electrochemical aptasensor based on an optimized MOX-specific aptamer (MOX-Opt) was developed for the ultrasensitive and selective detection of MOX. The biosensor was electrochemically characterized using cyclic voltammetry and electrochemical impedance spectroscopy. Under optimized conditions, a linear response was observed between 101 and 106 fM, with a limit of detection (LOD) of 3.92 fM. The selectivity of the aptasensor was assessed against structurally related antibiotics, Levofloxacin and Ciprofloxacin, demonstrating high specificity for MOX. To evaluate real-world applicability, MOX was successfully detected in artificial urine, artificial serum, and pharmaceutical formulations (Moxidexa® and Avelox®), achieving LODs of 0.047 fM, 0.50 fM, 6.15 fM, and 0.11 fM, respectively. Relative error studies further confirmed the reliability of the biosensor…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.